POTELIGEO 4 mg/mL concentrate for solution for infusion clinical trials

Open-Label, Phase 2 Study to Assess the Safety of Mogamulizumab Given Every 4 Weeks Following Induction in Participants with Relapsed/Refractory Cutaneous T-Cell Lymphoma (CTCL)

This study looks at a new drug called mogamulizumab (Poteligeo) for people with a type of skin lymphoma that has come back or is hard to treat. It is an early-stage study focusing on how safe the drug is when given every four weeks after initial treatment.